Welcome to our dedicated page for SEELOS THERAPEUTICS news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on SEELOS THERAPEUTICS stock.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel therapeutic solutions for central nervous system (CNS) disorders and rare ailments. Based in New York, the company's primary focus is on innovative technologies aimed at treating conditions like major depressive disorder (MDD), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and more.
Key developments in Seelos' pipeline include:
- SLS-002: An intranasal racemic ketamine targeting acute suicidal ideation and behavior in MDD and PTSD patients. This promising treatment has shown significant efficacy in Phase II trials, with plans for Phase III trials underway.
- SLS-005: A protein stabilizer for treating Sanfilippo syndrome and ALS. Recent trials in collaboration with the HEALEY ALS Platform have highlighted its potential benefits, even though some endpoints were not statistically significant.
- SLS-006: A partial dopamine agonist developed for PD patients, emphasizing symptom relief and improved quality of life.
- Preclinical Programs: These include SLS-007, an anti-alpha-synuclein inhibitor for PD; SLS-008, targeting chronic inflammation in asthma and pediatric orphan indications; and SLS-004 and SLS-010 for PD and narcolepsy, respectively.
Seelos Therapeutics actively engages in various clinical trials and collaborations to advance its therapeutic offerings. The company recently announced public offerings and strategic financial maneuvers to support its robust pipeline, including offerings totaling approximately $10.65 million in gross proceeds. These funds are earmarked for advancing Seelos' clinical programs and general corporate purposes.
Committed to addressing unmet medical needs, Seelos Therapeutics is poised to make significant contributions to the biopharmaceutical landscape, with a keen focus on CNS disorders and rare diseases.
Seelos Therapeutics (Nasdaq: SEEL) announced a collaboration with the Sean M. Healey & AMG Center for ALS for an Expanded Access Program (EAP) funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS. This program aims to study SLS-005 in ALS patients who do not qualify for clinical trials, enrolling 70 patients over 24 weeks. The initiative supports ongoing clinical research and aims to collect additional data on SLS-005’s efficacy in treating this devastating disease.
Acadia Healthcare (NASDAQ: ACHC) announced that select facilities will participate in a trial studying suicidal ideation and behavior in major depression, sponsored by Seelos Therapeutics (NASDAQ: SEEL) for the SLS-002 drug. This drug, an intranasal ketamine, aims to address an unmet need for treating these conditions. The trial includes a five-dose treatment regimen over 15 days. Acadia's involvement underscores its mission to deliver innovative care, with promising preliminary results for SLS-002.
Seelos Therapeutics (SEEL) has announced the participation of Acadia Healthcare (ACHC) in a registration-directed Proof of Concept study for SLS-002, intranasal racemic ketamine, targeting Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). This collaborative effort seeks to evaluate the efficacy and safety of SLS-002 in patients at imminent risk of suicide. Acadia operates a well-established network of behavioral health facilities, treating thousands daily, enhancing the study's potential impact.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29, 2022. CEO Raj Mehra will engage in 1x1 investor meetings and a fireside chat on September 28 at 2:45 PM ET, hosted by analyst Yatin Suneja. The company focuses on developing therapies for central nervous system disorders and rare diseases, with projects addressing various conditions including Major Depressive Disorder and amyotrophic lateral sclerosis. A webcast of the fireside chat is available online.
Seelos Therapeutics (Nasdaq: SEEL) announced participation in two key psychedelic conferences focusing on mental health treatments. The events, Jefferies Innovation in Mental Health Summit on September 22nd and Cantor Neurology and Psychiatry Conference on October 6th, will feature discussions about the clinical study of SLS-002, an intranasal racemic ketamine designed to treat suicidality in patients with Major Depressive Disorder. SLS-002 is noteworthy for being the only drug in its class currently in a registrational study targeting Acute Suicidal Ideation and Behavior.
Seelos Therapeutics (Nasdaq: SEEL) has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to advance the preclinical development of its gene therapy, SLS-004. This program targets the SNCA gene, which is linked to alpha-synuclein expression and Parkinson's disease. Previous studies showed promising results with significant reductions in SNCA mRNA and protein levels. The CEO, Raj Mehra, emphasized the grant's importance in enhancing the program's visibility and impact. Further data from ongoing preclinical studies is expected later this year.
Seelos Therapeutics (Nasdaq: SEEL) announced the dosing of the first patient in an open-label study of SLS-005 for treating amyotrophic lateral sclerosis (ALS) in Australia. This 24-week study aims to assess the treatment's effectiveness and safety across multiple neurological disorders. The HEALEY ALS Platform trial is also actively enrolling, with full enrollment expected by the quarter's end. SLS-005 is a trehalose injection that shows promise in reducing protein misfolding and is currently investigational.
Seelos Therapeutics (Nasdaq: SEEL) announced a significant advancement in its gene therapy program SLS-004, showing a 19% downregulation of mRNA and a ~40% reduction of alpha-synuclein in an in vitro study targeting dementia with Lewy bodies (DLB). The results, with a statistical significance of p<0.01, support further preclinical studies. CEO Raj Mehra expressed excitement over the findings, emphasizing their potential efficacy, and indicated plans to release more detailed data in the second half of this year.
Seelos Therapeutics (Nasdaq: SEEL) announced on May 18, 2022, that it has received a Notice of Allowance from the USPTO for U.S. patent application number 16/833,515, covering SLS-007. This patent focuses on treating neurodegenerative diseases like Alzheimer's and Parkinson's by targeting alpha-synuclein aggregation. SLS-007 is being delivered via an adeno-associated virus in a preclinical study aimed at determining its pharmacokinetic and pharmacodynamic profiles. Preliminary data is anticipated in the second half of 2022.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the 2022 Jefferies Global Healthcare Conference from June 8-10, 2022. Raj Mehra, Ph.D., CEO, and Michael Golembiewski, CFO, will present on June 10 at 12:00 PM ET and engage in one-on-one meetings. This conference will host over 500 healthcare companies and 3,000 investors to discuss investment opportunities and trends in the healthcare sector. For additional details regarding the presentation, registration can be accessed here.
FAQ
What is the current stock price of SEELOS THERAPEUTICS (SEEL)?
What is the market cap of SEELOS THERAPEUTICS (SEEL)?
What does Seelos Therapeutics, Inc. do?
What are the key products in Seelos Therapeutics' pipeline?
What recent achievements has Seelos Therapeutics made?
How does SLS-002 work?
What is the financial status of Seelos Therapeutics?
Who are Seelos Therapeutics' key partners?
What is SLS-005, and what does it treat?
What is the status of SLS-005 in clinical trials?
How is Seelos Therapeutics funded?
What are the future plans for Seelos Therapeutics?
